The Journal of Practical Medicine >

2026 , Vol. 42 >Issue 8: 1341 - 1346

DOI: https://doi.org/10.3969/j.issn.1006-5725.2026.08.005

Chronic Disease Control

Predictive value of combined pulmonary artery pulsatility index and myocardial microcirculation indicators for major adverse cardiovascular events in elderly patients with chronic heart failure with reduced ejection fraction

  • Guoqiu WANG ,
  • Liyong GE ,
  • Anning ZENG ,
  • Qinyu YANG ,
  • Wei LI
Expand
  • 1.Clinical Medical College of Guizhou Medical University，Guiyang 55000，Guizhou，China
    2.Department of Cardiovascular Medicine，Affiliated Hospital of Guizhou Medical University，Guiyang 550000，Guizhou，China
    3.Department of Cardiovascular Medicine，People's Hospital of Qiannan Buyi and Miao Autonomous Prefecture，Duyun 558000，Guizhou，China

Received date: 2025-12-08

  Online published: 2026-04-28

Fold

Abstract

Objective To investigate the prognostic value of combined assessment of the pulmonary artery pulsatility index （PAPi） and the myocardial microcirculation index in elderly patients with chronic heart failure with reduced ejection fraction （HFrEF）. Methods From January 2024 to January 2025， 108 elderly HFrEF patients were enrolled， with the mean age of （72.37 ± 6.54） years. Patients underwent a 6-month follow-up period， and the occurrence of major adverse cardiovascular events （MACE） was recorded. Clinical characteristics， hemodynamic parameters and myocardial microcirculation index were compared between MACE and non-MACE groups. Independent risk factors for MACE were identified using multivariate logistic regression， and receiver operating characteristic （ROC） curve was employed to assess predictive performance. Results During follow-up， 32 patients （29.63%） experienced MACE. Compared with the non-MACE group， the MACE group exhibited significantly higher age and atrial fibrillation incidence （P < 0.05）. The MACE group had lower PAPi but higher total myocardial ischemia burden and CSI scores than the non-MACE group （P < 0.05）. Multivariate logistic regression identified PAPi， total myocardial ischemia burden， and CSI score as independent predictors of MACE （P < 0.05）. ROC analysis showed that the combination of these 3 indicators achieved an area under the curve （AUC） of 0.948（95%CI： 0.888 - 0.982）， significantly higher than that of PAPi （AUC = 0.863， 95%CI： 0.784 - 0.922）， total myocardial ischemia burden （AUC = 0.914， 95%CI： 0.844 - 0.959）， CSI score （AUC = 0.760， 95%CI： 0.668 - 0.837） when used alone （all P < 0.05）. The combined test demonstrated a sensitivity of 84.37% and specificity of 96.05%. Conclusions PAPi， total myocardial ischemia burden and CSI score represent risk factors for MACE in elderly HFrEF patients. Their combined assessment provides high clinical value for predicting prognosis in this population.

Key words： pulmonary artery pulsatility index; myocardial microcirculation; heart failure; elderly; major adverse cardiovascular events

Cite this article

Guoqiu WANG , Liyong GE , Anning ZENG , Qinyu YANG , Wei LI . Predictive value of combined pulmonary artery pulsatility index and myocardial microcirculation indicators for major adverse cardiovascular events in elderly patients with chronic heart failure with reduced ejection fraction[J]. The Journal of Practical Medicine, 2026 , 42(8) : 1341 -1346 . DOI: 10.3969/j.issn.1006-5725.2026.08.005

References

[1] HEIDENREICH P A， BOZKURT B， AGUILAR D， et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure： A Report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines［J］. Circulation， 2022， 145（18）： e895-e1032.doi： 10.1161/CIR.0000000000001063 .
[2] KANG K， WANG Q， LI Y， et al. Global and Chinese perspectives on the growing burden of heart failure： Trends， gender， and age-related differences （1990-2021） based on GBD 2021 data［J］. BMC Cardiovasc Disord， 2025， 25（1）： 510.doi： 10.1186/s12872-025-04954-8 .
[3] HELBITZ A， NADARAJAH R， MU L， et al. Identification， characterisation and outcomes of pre-atrial fibrillation in heart failure with reduced ejection fraction［J］. ESC Heart Fail， 2025， 12（5）： 3688-3696.doi： 10.1002/ehf2.15347 .
[4] ROSANO G M C， TEERLINK J R， KINUGAWA K， et al. The use of left ventricular ejection fraction in the diagnosis and management of heart failure. A clinical consensus statement of the Heart Failure Association （HFA） of the ESC， the Heart Failure Society of America （HFSA）， and the Japanese Heart Failure Society （JHFS）［J］. Eur J Heart Fail， 2025， 27（7）：1174-1187.doi： 10.1002/ejhf.3646 .
[5] 伍鑫，丁戈琦，李禄丰，等. 血清可溶性生长刺激表达因子2、氨基末端B型脑钠肽前体及超声心动图参数与急性心肌梗死后心力衰竭患者心肌重塑的关系［J］. 实用医学杂志， 2025， 41（19）： 3034-3040.doi：10.3969/j.issn.1006-5725.2025.19.011 .
[6] SONG C， YUAN S， CUI K， et al. Prognostic value of N-terminal Pro-B-Type natriuretic peptide in patients with intermediate coronary lesions［J］. Front Cardiovasc Med， 2022， 9： 903757.doi：10.1016/j.amjcard.2006.12.071 .
[7] ESSANDOH M， KUMAR N， HUSSAIN N， et al. Pulmonary artery pulsatility index as a predictor of right ventricular failure in left ventricular assist device recipients： A systematic review［J］. J Heart Lung Transplant， 2022， 41（8）： 1114-1123.doi： 10.1016/j.healun.2022.04.007 .
[8] YILDIZ O， BAYDAR O. Prognostic value of pulmonary artery pulsatility index in chronic heart failure patients with reduced ejection fraction［J］. Acta Cardiol， 2022， 77（5）： 408-415.doi： 10.1080/00015385.2021 .
[9] LI Y， YU J， WANG Y. Mechanism of Coronary Microcirculation Obstruction after Acute Myocardial Infarction and Cardioprotective Strategies［J］. Rev Cardiovasc Med， 2024， 25（10）： 367.doi： 10.31083/j.rcm2510367 .
[10] BEGHINI A， SAMMARTINO A M， PAPP Z， et al. 2024 update in heart failure［J］. ESC Heart Fail， 2025， 12（1）： 8-42.doi： 10.1002/ehf2.14857 .
[11] LYHNE M D， YURIDITSKY E， ZOCHIOS V， et al. Pulmonary artery pulsatility index in acute and chronic pulmonary embolism［J］. Medicina （Kaunas）， 2025， 61（2）： 363.doi： 10.3390/medicina61020363 .
[12] WEN Y， ZHANG Y， LV Q， et al. The effect of individual exercise rehabilitation program on ischemic burden and cardiac function in patients with ischemic non-obstructive coronary heart disease： A randomized parallel controlled clinical trial［J］. Front Cardiovasc Med， 2025， 12： 1421923.doi： 10.3389/fcvm.2025.1421923 .
[13] 靳文英，朱天刚，王岚，等. 急性心肌梗死患者介入术后早期超声心肌灌注评分与心功能的相关性［J］. 中国超声医学杂志， 2022， 38（4）： 398-401.doi：10.3969/j.issn.1002-0101.2022.04.010
[14] HEIDENREICH P. Heart failure management guidelines： New recommendations and implementation［J］. J Cardiol， 2024， 83（2）：67-73.doi： 10.1016/j.jjcc.2023.10.009 .
[15] GUAZZI M， NAEIJE R. Right heart phenotype in heart failure with preserved ejection fraction［J］. Circ Heart Fail， 2021， 14（4）： e007840.doi： 10.1161/CIRCHEARTFAILURE.120.007840 .
[16] JUDINA A， NIGLAS M， LEONOV V， et al. Pulmonary hypertension-associated right ventricular cardiomyocyte remodelling reduces treprostinil function［J］. Cells， 2023， 12（23）： 2764.doi： 10.3390/cells12232764 .
[17] LYHNE M D， YURIDITSKY E， ZOCHIOS V， et al. Pulmonary artery pulsatility index in acute and chronic pulmonary embolism［J］. Medicina （Kaunas）， 2025， 61（2）： 363.doi： 10.3390/medicina61020363 .
[18] MONTEAGUDO-VELA M， TINDALE A， MONGUIó-SANTíN E， et al. Right ventricular failure： Current strategies and future development［J］. Front Cardiovasc Med， 2023， 10： 998382.doi： 10.3389/fcvm.2023.998382 .
[19] 陈亚南，郭秋红，姜涛，等. 冠心舒通胶囊对急性ST段抬高型心肌梗死急诊介入术后微循环功能以及预后的影响［J］. 实用医学杂志， 2021， 37（5）： 671-675.doi：10.3969/j.issn.1006-5725.2021.05.022 .
[20] ZERN E K， WANG D， RAMBARAT P， et al. Association of pulmonary artery pulsatility index with adverse cardiovascular events across a hospital-based sample［J］. Circ Heart Fail， 2022， 15（2）： e009085.doi： 10.1161/CIRCHEARTFAILURE.121.009085 .
[21] KUMAR R， SAFDAR U， YAQOOB N， et al. Assessment of the prognostic performance of TIMI， PAMI， CADILLAC and GRACE scores for short-term major adverse cardiovascular events in patients undergoing emergent percutaneous revascularisation： A prospective observational study［J］. BMJ Open， 2025， 15（3）： e091028.doi： 10.1136/bmjopen-2024-091028 .
[22] IANNACCONE M， S?AWEK-SZMYT S， GAMARDELLA M， et al. The role of Pulmonary Artery Pulsatility Index to assess the outcomes following catheter directed therapy in patients with intermediate-to-high and high-risk pulmonary embolism［J］. Cardiovasc Revasc Med， 2026，82： 57-61.doi： 10.1016/j.carrev.2025.02.002 .
[23] NICOLAU A M， SILVA P G， MEJíA H P G， et al. Molecular Mechanisms of Microvascular Obstruction and Dysfunction in Percutaneous Coronary Interventions： From Pathophysiology to Therapeutics-A Comprehensive Review［J］. Int J Mol Sci 2025， 26（14）： 6835.doi： 10.3390/ijms26146835 .
[24] SEN P， WANG L， D'AMBROSIO L， et al. Coronary microvascular disease in heart failure with preserved ejection fraction［J］. Physiol Rep， 2025， 13（16）： e70521.doi： 10.14814/phy2.70521 .
[25] SINGH A， ASHRAF S， IRFAN H， et al. Heart failure and microvascular dysfunction： An in-depth review of mechanisms， diagnostic strategies， and innovative therapies［J］. Ann Med Surg （Lond）， 2024， 87（2）：616-626. doi： 10.1097/MS9.0000000000002971 .
Options
Outlines

/

〈 〉